Axa S.A. Adaptimmune Therapeutics PLC Transaction History

Axa S.A.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2018 May 14, 2018	SELL	$7.1 - $11.56 $2.1 Million - $3.42 Million	-295,926 Closed	0 $0
Q4 2017 Feb 13, 2018	SELL	$6.68 - $8.74 $2.67 Million - $3.49 Million	-399,056 Reduced 57.42%	295,926 $1.98 Million
Q3 2017 Nov 13, 2017	BUY	$4.93 - $8.93 $3.43 Million - $6.21 Million	694,982	694,982 $5.69 Million

150M

60.8K

5.8K

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $111M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.